SPART
Spartin
Also known as: KIAA0610, SPART_HUMAN, SPG20, TAHCCP1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8N0X7
- Gene
- SPART
- Ensembl
- ENSG00000133104
- Chromosome
- 13
- Canonical length
- 666 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins
- Subcellular location
- Cytosol
OverviewNCBI Gene
This gene encodes a protein containing a MIT (Microtubule Interacting and Trafficking molecule) domain, and is implicated in regulating endosomal trafficking and mitochondria function. The protein localizes to mitochondria and partially co-localizes with microtubules. Stimulation with epidermal growth factor (EGF) results in protein translocation to the plasma membrane, and the protein functions in the degradation and intracellular trafficking of EGF receptor. Multiple alternatively spliced variants, encoding the same protein, have been identified. Mutations associated with this gene cause autosomal recessive spastic paraplegia 20 (Troyer syndrome). [provided by RefSeq, Nov 2008]
Canonical amino-acid sequenceUniProt
666 residues, UniProt reviewed canonical sequence.
>Q8N0X7|SPART
1 MEQEPQNGEP AEIKIIREAY KKAFLFVNKG LNTDELGQKE EAKNYYKQGI GHLLRGISIS
61 SKESEHTGPG WESARQMQQK MKETLQNVRT RLEILEKGLA TSLQNDLQEV PKLYPEFPPK
121 DMCEKLPEPQ SFSSAPQHAE VNGNTSTPSA GAVAAPASLS LPSQSCPAEA PPAYTPQAAE
181 GHYTVSYGTD SGEFSSVGEE FYRNHSQPPP LETLGLDADE LILIPNGVQI FFVNPAGEVS
241 APSYPGYLRI VRFLDNSLDT VLNRPPGFLQ VCDWLYPLVP DRSPVLKCTA GAYMFPDTML
301 QAAGCFVGVV LSSELPEDDR ELFEDLLRQM SDLRLQANWN RAEEENEFQI PGRTRPSSDQ
361 LKEASGTDVK QLDQGNKDVR HKGKRGKRAK DTSSEEVNLS HIVPCEPVPE EKPKELPEWS
421 EKVAHNILSG ASWVSWGLVK GAEITGKAIQ KGASKLRERI QPEEKPVEVS PAVTKGLYIA
481 KQATGGAAKV SQFLVDGVCT VANCVGKELA PHVKKHGSKL VPESLKKDKD GKSPLDGAMV
541 VAASSVQGFS TVWQGLECAA KCIVNNVSAE TVQTVRYKYG YNAGEATHHA VDSAVNVGVT
601 AYNINNIGIK AMVKKTATQT GHTLLEDYQI VDNSQRENQE GAANVNVRGE KDEQTKEVKE
661 AKKKDKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SPART can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.46
- Highest tissue expression
- 63 nTPM
Expression across tissuesHPA
Tissue
- epididymis: 63 nTPM
- ovary: 63 nTPM
- blood vessel: 51 nTPM
- smooth muscle: 49 nTPM
- spinal cord: 49 nTPM
- cervix: 46 nTPM
Single-cell type
- early spermatids: 258 nCPM
- choroid plexus epithelial cells: 235 nCPM
- late primary spermatocytes: 227 nCPM
- oligodendrocytes: 220 nCPM
- pituicytes/fscs: 214 nCPM
- leydig cells: 172 nCPM
Immune cell
- basophil: 173 nTPM
- neutrophil: 35 nTPM
- eosinophil: 30 nTPM
- naive CD4 T-cell: 25 nTPM
- non-classical monocyte: 24 nTPM
- classical monocyte: 22 nTPM
Brain region
- white matter: 63 nTPM
- cerebellum: 50 nTPM
- choroid plexus: 47 nTPM
- medulla oblongata: 47 nTPM
- basal ganglia: 47 nTPM
- spinal cord: 45 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SPART.
Disease | AllUniProt
Conditions SPART is implicated in, by any mechanism.
- Spastic paraplegia 20, autosomal recessive (SPG20) MIM:275900
Disease | GeneticClinVar
28 pathogenic / likely-pathogenic of 416 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Troyer syndrome
- Neurodevelopmental delay
- SPART-related disorder
- Inborn genetic diseases
- 6 conditions
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.84
- gnomAD pLI
- 0
- DepMap mean gene effect
- 0.02
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adipose tissue development
- BMP signaling pathway
- cell division
- collateral sprouting in absence of injury
- lipid catabolic process
- lipid droplet organization
- lipid transport
- lipophagy
- midbody abscission
- negative regulation of BMP signaling pathway
- neuromuscular process
- regulation of mitochondrial membrane potential
- negative regulation of collateral sprouting in absence of injury
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- MIT domain
- MIT domain superfamily
- Senescence/spartin-associated, C-terminal
- Spartin-like
- Senescence domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SPART in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SPART as an antibody target. Whether an autoantibody or antibody against SPART could matter depends on whether native SPART is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SPART is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SPART as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...